So far, xx procedures concerning xx different medicinal products have been finalised by the G-BA following an early benefit assessment. The decisions entered into force after being published in the Federal Gazette (Bundesanzeiger). On the procedure level, i.e. without taking individual subpopulations into account and using the highest benefit as the basis, the following results can be obtained: According to the G-BA approximately xx% of the medicinal produts were able to show a major additional benefit and further xx% a considerable additional benefit. xx% of the assessed products offered a minor additional benefit and xx% a non-quantifiable additional benefit. The G-BA found no additional benefit for xx% of the innovative medicinal products and for xx% less benefit than the appropriatce comparative therapy.